Mobile Early Social Interaction Coaching for Toddler Autism
(ESI-MC Trial)
Trial Summary
What is the purpose of this trial?
The goal of this collaborative R01 is to demonstrate the therapeutic value and community-wide implementability of an early intervention (EI) platform for toddlers with autism spectrum disorder (ASD) that is completely virtual, from recruitment through intervention. This platform-Early Social Interaction Mobile Coaching (ESI-MC) deploys individual telehealth sessions with coaching and feedback to help families embed intervention in everyday activities. Specifically, the investigators will conduct an effectiveness trial of ESI-MC to address the important question of whether starting evidence-based intervention earlier leads to better outcomes than starting later. The investigators will address this question by using a modified stepped wedge design and blended implementation research to analyze data obtained with ESI-MC start at 18, 24, or 30 months. The investigators will diagnostically ascertain 240 children from a pool of 360 18-month-olds with early signs of autism, 30 in each of 8 US regions (Central and SW Florida; Atlanta, GA; suburbs of Philadelphia, PA; New York City, NY; Cincinnati, OH; Chicago, IL; Seattle, WA; and Los Angeles, CA). Research participants will be recruited using a new virtual platform-My Baby Navigator-linking a new surveillance and screening tool, an app to upload video-recorded home observations and telehealth intervention sessions, and a package of educational resources. The 240 children will be randomly assigned to one of three ESI-MC timing groups. ESI-MC will be delivered by community-based early intervention providers (EIPs) currently working within the the early intervention system in the recruitment regions. The investigators will measure child active engagement and social communication change every 6 months as the primary outcome variables. Outcome measures of developmental level, autism symptoms, and adaptive behavior will be examined to measure differential treatment effects. Maximizing the use of mobile technology, ESI-MC offers the prospect of a community-viable, scalable and sustainable treatment to improve EI services for toddlers with ASD, particularly among minority and low-resource communities.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications. It is best to consult with the trial coordinators for specific guidance.
What data supports the effectiveness of the treatment Early Social Interaction Mobile Coaching (ESI-MC) for toddler autism?
Research shows that early interventions like the Early Social Interaction model can improve social skills and language development in toddlers with autism. Studies have found that similar treatments, such as the Early Start Denver Model, lead to better social communication and reduced parental stress, highlighting the importance of early, evidence-based interventions.12345
How is the Early Social Interaction Mobile Coaching (ESI-MC) treatment different from other treatments for toddler autism?
The Early Social Interaction Mobile Coaching (ESI-MC) treatment is unique because it focuses on coaching caregivers to actively engage with their toddlers, enhancing social communication skills through a mobile platform, which makes it more accessible and community-friendly compared to traditional in-person therapies.13456
Research Team
Amy Wetherby, PhD
Principal Investigator
Florida State University
Eligibility Criteria
This trial is for toddlers around 18 months old showing early signs of autism, living near one of the eight US recruitment sites. They must have a risk indication for autism from specific assessments and their home's primary language should be English or Spanish. Children with significant motor, visual, or hearing impairments, very low birth weight, medical complications like seizures, or those already in Early Intervention are excluded.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Early Social Interaction Mobile Coaching (ESI-MC) via telehealth sessions for 6 months, focusing on parent-implemented interventions for toddlers with ASD.
Follow-up
Participants are monitored for changes in social communication, autism symptoms, and adaptive behavior.
Long-term Follow-up
Exploration of outcomes at 36 months and individual patterns of change from 18-36 months.
Treatment Details
Interventions
- Early Social Interaction Mobile Coaching (ESI-MC) (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Florida State University
Lead Sponsor
Jim Scholefield
Florida State University
Chief Executive Officer since 2023
Bachelor of Science in Management from Florida State University
Dr. Stanley Iyadurai
Florida State University
Chief Medical Officer since 2023
MD and PhD from University of Minnesota
National Institute of Mental Health (NIMH)
Collaborator
Dr. Joshua A. Gordon
National Institute of Mental Health (NIMH)
Chief Executive Officer since 2016
MD, PhD
Dr. Shelli Avenevoli
National Institute of Mental Health (NIMH)
Chief Medical Officer
PhD
Children's Healthcare of Atlanta
Collaborator
Donna Hyland
Children's Healthcare of Atlanta
Chief Executive Officer since 2008
Bachelor of Science in Management from Georgia Tech, MBA from Northwestern University’s Kellogg School of Management
Dr. Srikant Iyer
Children's Healthcare of Atlanta
Chief Medical and Quality Officer
MD from the University of North Carolina at Chapel Hill, Master of Public Health from Harvard University
Weill Medical College of Cornell University
Collaborator
Dr. Robert Min
Weill Medical College of Cornell University
Chief Executive Officer since 2024
MD, MBA
Dr. Adam R. Stracher
Weill Medical College of Cornell University
Chief Medical Officer since 2024
MD
University of Pennsylvania
Collaborator
Dr. Joan Lau
University of Pennsylvania
Chief Executive Officer since 2020
PhD in Neuroscience from the University of Cincinnati College of Medicine, MBA from the Wharton School of Business, BS in Bioengineering from the University of Pennsylvania
Dr. Robert Iannone
University of Pennsylvania
Chief Medical Officer since 2019
MD from Yale University, MSCE from the University of Pennsylvania
Seattle Children's Hospital
Collaborator
Dr. Jeff Sperring
Seattle Children's Hospital
Chief Executive Officer since 2015
MD from Indiana University School of Medicine
Dr. Jeff Ojemann
Seattle Children's Hospital
Chief Medical Officer since 2022
MD from Washington University in St. Louis
Seattle Children's Hospital Research Institute
Collaborator
Emory University
Collaborator
Dr. R. Donald Harvey
Emory University
Chief Medical Officer
MD from Emory University School of Medicine
Dr. George Painter
Emory University
Chief Executive Officer since 2013
PhD in Synthetic Organic Chemistry from Emory University
Children's Hospital of Philadelphia
Collaborator
Joseph W. St. Geme III
Children's Hospital of Philadelphia
Chief Medical Officer since 2021
MD, PhD, MPH
Madeline Bell
Children's Hospital of Philadelphia
Chief Executive Officer since 2015
BSc in Nursing from Villanova University, MSc in Organizational Dynamics from the University of Pennsylvania
University of California, Los Angeles
Collaborator
Dr. Thomas Rando
University of California, Los Angeles
Chief Medical Officer since 2023
MD from UCLA
Amir Naiberg
University of California, Los Angeles
Chief Executive Officer since 2024
JD from UCLA